Growth on stimulant medication: clarifying the confusion: a review

A Poulton

Aims: To get an overview of the studies of growth in height in children with attention deficit hyperactivity disorder (ADHD) treated with stimulant medication, to establish the consistencies and to try to resolve the discrepancies.

Methods: Twenty nine studies were reviewed following a Medline search: 22 related to children, six to late adolescents or adults, and one to children and adults.

Results: Children: Eleven studies gave results consistent with height attenuation on stimulant medication: eight were longitudinal, one was cross-sectional, and two showed growth rebound on ceasing medication. Studies with negative findings were inadequately powered (n = 3), lacked controls or statistical analysis (n = 3), measured height velocity without reference to treatment duration (n = 2), or used inappropriate growth parameters (n = 1), controls (n = 1), or normative data (n = 1). Late adolescents/adults treated with stimulant medication in childhood: Two studies associated childhood gastrointestinal side effects with attenuated late adolescent or adult height; all six cross-sectional studies had negative findings. The methodologies varied widely but there was some consistency in the degree of attenuation shown in studies with positive findings. The most sensitive methods analysed the changes in z-scores (standard deviation scores) or calculated the height deficits from paired measurements taken before and after an initial period of treatment with stimulant medication. The height deficit amounted to approximately 1 cm/year during the first 1–3 years of treatment.

Conclusions: Further research is needed into the causal mechanisms, the rate of physical maturation, and the long term implications for final stature.

S

SS

stimulant medication was first suspected to have an adverse effect on growth in height in children with ADHD by a school nurse Evelyn Barr. Following her observations, Safer and Allen published studies in the 1970s showing early weight loss and growth in height that remained slower than controls for the first three years of treatment. Rebound growth on ceasing medication was also shown. Safer and Allen’s work was followed by a spate of studies, some replicating their results and others showing little effect on growth in height, although weight loss on starting stimulant medication has been a usual finding. As a result of ongoing discrepancies in the published literature, knowledge in this important area has advanced very little over the past 30 years and this topic remains one of confusion and controversy.

The purpose of this paper was to get an overview of the studies of growth in height in children with ADHD, to establish the consistencies, and to try to resolve the discrepancies. The effect of stimulant medication on growth in weight was not examined because it is more widely regarded as less serious as weight can be regained later. transient weight loss, and because fluctuations in weight are often regarded as less serious as weight can be regained later.

METHODS
A Medline search up to September 2004 was conducted using the keyword “growth” combined with “ADHD”, “methylphenidate”, or “dexamphetamine”. Reference lists of the articles were also screened. Studies reviewed were all cohort studies of children with ADHD treated with methylphenidate or dexamphetamine, or of adults treated as children. Studies were excluded if they had less than 10 subjects or lacked sufficient details for some analysis of the methodology. Data on pemoline were not included as this is used less frequently due to the risk of adverse effects.

Studies were classified, analysed, and evaluated according to the study design and whether the subjects were children or late adolescents/adults.

RESULTS
Twenty nine studies met the selection criteria. There were 22 studies of children, six studies of adults or adolescents close to their adult height, and one study that included both children and adults. Some studies have been published in two stages and therefore have two separate references. Seven studies related only to boys, one only to girls, and the remainder included both boys and girls or only specified “children”. The adult studies consisted either exclusively or predominantly of men.

Studies in children
Table 1 summarises 21 studies in children classified by the study design. Nine of these gave results consistent with statistically significant attenuation of growth in height on stimulants and 12 had negative findings. In addition to these there were studies by Safer and colleagues and Klein and colleagues showing rebound growth on ceasing medication, implying that on medication growth had been attenuated.

Dose of stimulant medication
The dose of methylphenidate or methylphenidate equivalent (calculated by doubling the dose of dexamphetamine) for the nine studies in Table 1 showing statistically significant attenuation ranged from 21.6 to 42 mg (median 31.4 mg). For the 12 studies with negative findings, the range for the nine which specified mean dosage was 18.4–34 mg (median 23.9 mg). Studies using lower doses of methylphenidate...
Table 1  Summary of the methodology and results of 21 stimulant growth studies in children

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Control</th>
<th>Treatment (mg/day)</th>
<th>n</th>
<th>Δ Height centile</th>
<th>Δ Height z-score</th>
<th>Δ Calculated adult height</th>
<th>Height deficit (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safer and Allen, 1973</td>
<td>Longitudinal from onset of treatment with stimulant</td>
<td>Untreated children with ADHD or normal children</td>
<td>Mph &gt;20</td>
<td>10</td>
<td>p&lt;0.05 (3 years)</td>
<td>NS</td>
<td></td>
<td>1.0 cm/year*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mph &lt; 20, Dex 12.5</td>
<td>29</td>
<td>p&lt;0.005 (2.9 years)</td>
<td>NS</td>
<td></td>
<td>1.5 cm/year*</td>
</tr>
<tr>
<td>Koala et al., 1982</td>
<td>Longitudinal from onset of treatment with stimulant</td>
<td>Untreated children with ADHD or normal children</td>
<td>Mph 18.4, Dex 31.4</td>
<td>23 boys</td>
<td>NS</td>
<td>p=0.023 (1.2 years)</td>
<td></td>
<td>1.5 at 1.2 years</td>
</tr>
<tr>
<td>Spencer et al., 1992</td>
<td>Longitudinal from onset of treatment with stimulant</td>
<td>Untreated children with ADHD or normal children</td>
<td>Mph 21.6</td>
<td>84</td>
<td>Boys p&lt;0.01 (3 and 4 years)</td>
<td>Girls p=0.05 (3 years)</td>
<td></td>
<td>Bays 3–4 at 3 years</td>
</tr>
<tr>
<td>Lisska and Rivkees, 2003</td>
<td>Longitudinal from onset of treatment with stimulant</td>
<td>Partially treated children</td>
<td>Mph 34.4</td>
<td>222</td>
<td>NS</td>
<td>NS</td>
<td></td>
<td>1.05 at 14 months</td>
</tr>
</tbody>
</table>

Design: longitudinal from onset of treatment with stimulant
Control: normative data

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Control</th>
<th>Treatment (mg/day)</th>
<th>n</th>
<th>Δ Height centile</th>
<th>Δ Height z-score</th>
<th>Height deficit (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross, 1976</td>
<td>Longitudinal from onset of treatment with stimulant</td>
<td>Normative data</td>
<td>Mph 34, Dex 16.5</td>
<td>84</td>
<td>NS</td>
<td>1.03 at 1 year p&lt;0.001 0.1 at 2 years NS</td>
<td></td>
</tr>
<tr>
<td>Millichap, 1978</td>
<td>Longitudinal from onset of treatment with stimulant</td>
<td>Untreated children with ADHD or normal children</td>
<td>Mph 10–20</td>
<td>36 boys</td>
<td>NS</td>
<td>1.8 at 1 year p&lt;0.005</td>
<td></td>
</tr>
<tr>
<td>Satterfield et al., 1979</td>
<td>Longitudinal from onset of treatment with stimulant</td>
<td>Untreated children with ADHD or normal children</td>
<td>Mph 24.2</td>
<td>72 boys</td>
<td>NS</td>
<td>3.3 at 4 years p&lt;0.005</td>
<td></td>
</tr>
<tr>
<td>Koffman et al., 1979</td>
<td>Longitudinal from onset of treatment with stimulant</td>
<td>Untreated children with ADHD or normal children</td>
<td>Mph 20, Dex 20</td>
<td>50</td>
<td>NS</td>
<td>p&lt;0.025 (1 year)</td>
<td></td>
</tr>
<tr>
<td>Greenhill et al., 1981</td>
<td>Longitudinal from onset of treatment with stimulant</td>
<td>Untreated children with ADHD or normal children</td>
<td>Dex 21</td>
<td>13 boys</td>
<td>NS</td>
<td>p&lt;0.001 (2, 3, 4 years)</td>
<td></td>
</tr>
<tr>
<td>Mattes and Gittelman, 1983</td>
<td>Longitudinal from onset of treatment with stimulant</td>
<td>Untreated children with ADHD or normal children</td>
<td>Mph 41.3</td>
<td>56</td>
<td>NS</td>
<td>0.67 at 2 years NS</td>
<td></td>
</tr>
<tr>
<td>Godow et al., 1999</td>
<td>Longitudinal from onset of treatment with stimulant</td>
<td>Untreated children with ADHD or normal children</td>
<td>Mph 30</td>
<td>34</td>
<td>p&lt;0.001 (1½, 1½ years)</td>
<td>0.64 at 1½ year p&lt;0.001 2.33 at 2½ years p&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Poulton and Cowell, 2003</td>
<td>Longitudinal from onset of treatment with stimulant</td>
<td>Untreated children with ADHD or normal children</td>
<td>Mph 27, Dex 13.7</td>
<td>51</td>
<td>NS</td>
<td>1.17 at 1½ year</td>
<td></td>
</tr>
</tbody>
</table>

Design: longitudinal from onset of treatment with stimulant
Control: partially treated children

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Control</th>
<th>Treatment (mg/day)</th>
<th>n</th>
<th>Δ Height centile</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinn and Rapoport, 1975</td>
<td>Longitudinal from onset of treatment with stimulant</td>
<td>Partially treated children</td>
<td>Mph 20.6</td>
<td>23 boys</td>
<td>NS</td>
</tr>
</tbody>
</table>

Design: longitudinal from onset of treatment with stimulant
Control: none

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Control</th>
<th>Treatment (mg/day)</th>
<th>n</th>
<th>Δ Height centile</th>
<th>Height velocity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sund and Zeiner, 2002</td>
<td>Longitudinal study of children changing formulation</td>
<td>None</td>
<td>Mph 23.9, Dex 11.9</td>
<td>91 boys</td>
<td>NS</td>
<td></td>
</tr>
</tbody>
</table>

Design: longitudinal from onset of treatment with stimulant
Control: normative data

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Control</th>
<th>Duration of treatment prior to study</th>
<th>Treatment (mg/day)</th>
<th>n</th>
<th>Change in average height of cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wilens et al., 2003</td>
<td>Cross sectional</td>
<td>Untreated children with ADHD or normal children</td>
<td>Not stated (most were treated)</td>
<td>Mph 18–54</td>
<td>407 at start 229 at 1 year</td>
<td>NS</td>
</tr>
</tbody>
</table>

Design: cross sectional
Control: untreated children with ADHD or normal children

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Control</th>
<th>Duration of treatment prior to study</th>
<th>Treatment (mg/day)</th>
<th>n</th>
<th>Height z-score</th>
<th>Height velocity</th>
</tr>
</thead>
<tbody>
<tr>
<td>McNutt et al., 1976; 1977</td>
<td>Longitudinal study of children changing formulation</td>
<td>Normative data</td>
<td>9–47 months mean 30.3 Average 4 years follow up</td>
<td>Mph 19.8</td>
<td>20</td>
<td>p=0.03</td>
<td>NS</td>
</tr>
<tr>
<td>Spencer et al., 1996; 1998</td>
<td>Cross sectional</td>
<td>Partially treated children</td>
<td>Any treatment ever</td>
<td>110 boys</td>
<td>20</td>
<td>p=0.03</td>
<td>NS</td>
</tr>
<tr>
<td>Biederman et al., 2003</td>
<td>Cross sectional</td>
<td>Untreated children with ADHD or normal children</td>
<td>Any treatment ever</td>
<td>53 boys</td>
<td>Mph 38 (†)</td>
<td>NS</td>
<td></td>
</tr>
</tbody>
</table>

Design: cross sectional
Control: normative data

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Control</th>
<th>Duration of treatment prior to study</th>
<th>Treatment (mg/day)</th>
<th>n</th>
<th>Height centile</th>
</tr>
</thead>
<tbody>
<tr>
<td>Millichap and Millichap, 1975</td>
<td>Cross sectional</td>
<td>Normative data</td>
<td>1–5 years mean 2½ years</td>
<td>Mph 10–40</td>
<td>50</td>
<td>NS</td>
</tr>
<tr>
<td>Vincent et al., 1990</td>
<td>Cross sectional</td>
<td>Untreated children with ADHD or normal children</td>
<td>½–7 years</td>
<td>Mph 34</td>
<td>31</td>
<td>NS</td>
</tr>
</tbody>
</table>

n, number of subjects; Mph, methylphenidate daily dose; Dex, dexamphetamine/amphetamine daily dose; NS, method used but did not show statistically significant evidence of attenuated growth.

*The height deficits in Safer and Allen’s studies represent averaged annual deficits from children in their first, second, or third year of treatment.
†Average dose of methylphenidate or equivalent in subgroup of children who received a stimulant in past 2 years.
(20 mg/day or less) did not show a significant effect on growth in height. The studies that analysed dexamphetamine showed more attenuation in the first year than studies that combined both stimulants during analysis or used only methylphenidate.

**Growth parameters**

There was considerable variation in the parameters used for analysing growth, making it difficult to compare the results of the different studies. The most frequently used method that consistently indicated attenuated growth in height and was possible to compare between studies was the height deficit. A height deficit of 3 cm means that the child is 3 cm shorter than he would be if he had continued to grow at the expected rate. The height deficit can be calculated from the change in centile, the change in z-score, or in a clinical setting it can be estimated directly from the growth chart. The early study by Spencer and colleagues showed that the change in height z-score and the height deficit are more sensitive parameters for monitoring growth than the change in height centile, a method which distorts the data due to the non-linear relation between change in height and change in centile.

**Longitudinal studies**

The most sensitive design was the longitudinal study analysing paired observations taken before and after an initial period of treatment with stimulant medication. Table 1 indicates that half (8/16) of the studies with this methodology showed attenuated growth on stimulants by at least one method, most reliably the change in height z-score (significant in 3/3). The height deficit reached statistical significance in 5 of the 6 studies with sufficient detail for a p value.

The study with the most scientifically rigorous methodology was the MTA study in which children with ADHD were allocated at random into different treatment groups. The children who received stimulant medication had an average height deficit of 0.9 cm/year during the first 14 months and 1.04 cm/year from 14–24 months when compared with children whose treatment was non-pharmacological. Four other studies compared treated children with control groups consisting either of untreated children with ADHD or normal children. Three of the four studies with this design showed height attenuation by at least one method in at least one treatment group. The fourth, by Kalachnik and colleagues, calculated the projected adult stature using the Roche–Wainer–Thissen formula and analysed changes in this projection after 1–3 years of treatment. The formula takes into consideration mid-parental stature, and child’s weight and recumbent length, with regression coefficients for each of these which change with every six month age bracket. As a method for monitoring growth, this would not only add variability to the data due to the changing coefficients, but would also systematically undervalue attenuation of growth in height occurring in the presence of weight loss or poor weight gain. Both of these problems would increase the likelihood of failing to detect a significant effect (type II error).

Eight longitudinal studies used normative data as the control without confirming its validity for normal children. Three of these showed height attenuation of a magnitude reasonably consistent with the studies that used untreated children as controls, suggesting that the height velocities of the normative data may have been appropriate. By contrast the studies by Gross and Satterfield and colleagues used the Iowa Growth Tables, published in 1941, which have an average height velocity for boys aged 8–11 years that is 0.7 cm/year less than the 1976 National Centre for Health Statistics charts. This may explain the progressive gain in height centiles observed by Gross in all treatment groups and resolution of the height deficit in the second year of treatment in the study by Satterfield et al. The reason for the smaller height deficit of 0.67 cm in two years in the study by Gadow and colleagues is unclear. However, the statistical analysis used an unpaired t test instead of the more powerful paired t test, effectively reducing the power of this longitudinal study to that of a cross sectional study that compares unrelated groups. The study by Kalman and colleagues lacked rigorous analysis, only observing the numbers crossing certain centile lines on treatment. The study by Quinn and Rapoport compared treated children with controls who had received treatment for up to four months out of a 12 month study period. The unsupported assumption that any effect of stimulant medication on growth in the first four months would have normalised, combined with the small numbers and analysis using change in centile may explain the negative findings. The studies by Sund and Zeiner and Wilens and colleagues lacked any kind of control group for comparison. The study by Wilens et al had a 44% drop out rate which renders meaningless any comparison of the average height of the cohort before and after 12 months of treatment.

**Cross sectional studies**

Cross sectional studies lack the statistical power associated with comparing paired measurements of the same subjects before and after a period of treatment. Table 2 shows the estimated number in each group (subjects and controls) required for a cross sectional study to detect a height deficit of a magnitude comparable to those shown in table 1. This indicates that the study by Millichap and Millichap and the cross sectional analysis by Gadow and colleagues were inadequately powered, and the study by Biederman and colleagues had adequate power to detect a treatment effect only if the subjects had been treated for three years or more, information lacking in the published report. The study by Spencer and colleagues was the only cross sectional study to show a difference in height z-score between children with ADHD and normal children, and was the only adequately powered cross sectional study. This study is difficult to interpret due to the lack of information on treatment...
duration within the different treatment subgroups. Two studies analysed height velocity and without taking into consideration that this could vary with the duration of treatment.

**Studies of late adolescent and adult height of individuals treated in childhood**

There were five cross sectional studies looking at late adolescent or adult height and one looking at both children and adults. None showed any significant difference between those treated with stimulants in childhood and controls (table 3). One possible explanation is that the numbers may have been insufficient. Tables 2 and 3 suggest that five of the six studies may be inadequately powered, although the calculations used for table 2 may not be applicable to data on adult height. Another possibility is that there may have been catch up growth during puberty. The adults were still on stimulant medication in only one study, and in view of the observation that children ceasing treatment with stimulant medication may have accelerated growth, it is possible that some who ceased medication while still growing might have caught up.

Two studies used a retrospective longitudinal design, and by multiple regression analysis showed that 4.4% and 7% respectively of the variation in adult height and adolescent height was predictable from treatment side effects of appetite suppression, nausea, and vomiting. In the study by Kramer and colleagues this amounted to a deficit of 6.6 cm when compared to individuals without these side effects.

**DISCUSSION**

**Principle findings**

Many of the studies reviewed were of poor quality and would have been excluded had rigorous selection criteria been applied. There was clear evidence of an association between treatment with stimulant medication and attenuated growth in height in the better quality studies.

The most reliable method for showing attenuated growth was the longitudinal study analysing the changes in z-scores or calculating the height deficits from paired measurements taken before and after an initial period of treatment with stimulant medication. In studies that had untreated control groups the investigators did not have to make the assumption that the normative data was appropriate.

Cross sectional studies in children have tended to be under-powered, therefore their negative findings can be discounted.

While it might be desirable to combine the results of the studies in table 1 to get an accurate height deficit for the first, second, and third year of treatment, the time periods are too variable and there is insufficient data for this to be possible, although an average height deficit of approximately 1 cm/year during the first 1–3 years of treatment would appear to be a reasonable estimate. Further studies are needed to define the annual height deficits more precisely, relating these to the dose of stimulant medication. There is also a need for more long term studies with continuous follow up defining the growth pattern through adolescence until adult height is reached.

The effect of stimulant medication on growth in height may be dose dependent, attenuation being shown less frequently at doses not exceeding 20 mg/day of methylphenidate. Dexamphetamine may be associated with more attenuation than methylphenidate.

The finding that side effects of medication may be associated with a permanent adverse effect on growth is a cause of concern. This needs further study, looking at the early velocities for height and weight to find out if these are more attenuated in duration or degree in children with gastrointestinal side effects.

**Strengths and weaknesses**

This is the largest and most detailed review to date of the studies of growth in children with ADHD treated with dexamphetamine or methylphenidate. The inclusion criteria were broad as the intention was to include, rather than to exclude, the studies with poorer quality methodology. Once a study has been published in a reputable journal there is a risk that readers will assume the conclusions are correct without checking that they are supported by the data, that the methodology is appropriate, and that the study is adequately powered. It is important for the scientific integrity of the medical literature as a whole that the poorer studies do not stand without published critique.

Another strength of this review is in the classification of the studies according to their overall design. The results of each study were then examined in the context of the
methodology, reinterpreting the findings where appropriate rather than simply summarising the authors’ conclusions.

It was not possible to divide the studies in children into pre-adolescents and adolescents because the details were lacking, although there may be an important distinction between the effect of stimulants before and after the onset of puberty.

Some details such as the accuracy of the measurements and the appropriateness of the normative data for comparison in the individual studies have not been fully addressed.

Relation between attenuated growth in height and weight on stimulant medication and possible mechanisms

Studies comparing changes in height and weight have found reductions in centile scores in the first 1–2 years, with weight affected more than height. In the two studies of longer duration the weight centile stabilised but the height centile continued its decline for the third and fourth year. Safer and Allen found a significant correlation between the changes in centiles for height and weight, not replicated in some of the later studies. Poult. and Cowell found ratios of changes in z-scores of weight to height of 4.3, 2.2, 1.95, and 2.1 at 6, 18, 30, and 42 months respectively, the ratios stabilising but the z-scores continuing to decline into the third year. The correlation between the cumulative changes in z-scores for height and weight became closer with time: r = 0.39, 0.47, 0.88, and 0.97 at 6, 18, 30, and 42 months respectively. The closeness of this correlation would appear to indicate that stimulant medication affects both height and weight by a single mechanism.

Poult. and Cowell analysed the height velocity at different durations of treatment and found that it was slowest in the first six months, coinciding with the period with the fastest reduction in weight z-score. It may be hypothesised that as soon as the child goes into negative energy balance, growth in height is switched off to basal levels. The weight stabilises and then starts to increase, resuming a normal or near normal rate of weight gain after 1–2 years but at a lower weight or z-score. The height takes longer to adjust to this new equilibrium, normal velocities being attained after 2½–3½ years. The change in height z-score after 30 months of treatment may be predicted from the change in weight z-score after six months using the formula \( y = 0.47x - 0.17 \) where \( y \) is the change in height z-score after 30 months and \( x \) is the change in weight z-score after six months of treatment (Pearson’s correlation coefficient \( r = 0.76, p = 0.0017 \) using paired t test).

On cessation of medication one study has shown catch up growth in weight and height occurring together over a three month period and one study has shown initial catch up growth in weight without any catch up growth in height. This could be explained if weight gain drives growth in height after a variable lag phase, perhaps while body energy stores are being replenished. The MTA study did not show any catch up growth in children who came off their medication after the first 14 months: the growth rate for weight normalised in the subsequent 10 months and the height velocity remained attenuated. Children were classified as unmedicated from 10 to 24 months if they had ceased stimulant medication for at least one month at the time of the 24 month follow up. Some might therefore have received stimulant medication for a substantial part of this period, obscuring the effect of catch up growth in others.

It is possible that stimulant medication may activate mechanisms adapted for surviving acute starvation, conserving energy stores by restricting growth in height. No mediators for the effect of stimulant medication on growth have yet been identified but a starting point for research might be to look at hormones that may regulate the appetite.

It remains unclear whether the reduction in the height velocity represents a delay in physical maturation or whether children continue to mature physically at the normal rate. Longer term studies are needed, looking at the rate of progression of the bone age and pubertal development in children on stimulants.

Conclusions

The most noticeable point that comes out of this review is the plethora of studies, some from tertiary centres, that have failed to detect an adverse effect of stimulant medication on growth in height in children with ADHD, an effect that can readily be shown in a community setting using the most basic equipment. Studies vary widely in their methodology and this review has shown that many do not stand up to rigorous analysis.

The reasonable degree of consistency in the height deficit in studies with positive findings makes it implausible that this should be due to artefact. Doctors treating children with stimulant medication should therefore anticipate a reduction in the height velocity, and growth should be closely monitored. It would appear that most children achieve a satisfactory adult height, but there may be an important subgroup whose growth is permanently attenuated.
The confusion resulting from the discrepancies in the literature has diverted attention from the important question that follows on from this: what is the significance of the period of poor growth that many children experience when starting stimulant medication? There seems to be an assumption among clinicians that for most children the effect of stimulant medication on growth needs to be studied prospectively and over longer time periods looking into the causal mechanisms, the rate of physical maturation, and the long term implications for final stature.

ACKNOWLEDGEMENTS

I acknowledge Dr P Oakeshott for comments on the manuscript.

Competing interests: none

REFERENCES

35. Previously unpublished analysis of data from the same study as reference 15.

www.archdischild.com